Evidence map›Paper›PMID 38001691›Full record

ArticleCancers2023

Prognostic Impact of Copy Number Alterations' Profile and AID/RAG Signatures in Acute Lymphoblastic Leukemia (ALL) with BCR::ABL and without Recurrent Genetic Aberrations (NEG ALL) Treated with Intensive Chemotherapy.

Marta Libura, Karolina Karabin, Paweł Tyrna, Anna Czyż, Hanna Makuch-Łasica, Bożena Jaźwiec, Monika Paluszewska, Beata Piątkowska-Jakubas, Magdalena Zawada, Michał Gniot and 31 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

41 authors at 11 institutions in 1 country.

Marta LiburaDepartment of Hematology, Transplantation and Internal Medicine, Medical University of Warsaw, 02-091 Warsaw, Poland.
Karolina KarabinDepartment of Hematology, Transplantation and Internal Medicine, Medical University of Warsaw, 02-091 Warsaw, Poland.
Paweł TyrnaDepartment of Hematology, Transplantation and Internal Medicine, Medical University of Warsaw, 02-091 Warsaw, Poland.ORCID 0000-0003-2341-6976
Anna CzyżDepartment of Hematology, Blood Neoplasms and Bone Marrow Transplantation, Medical University of Wrocław, 50-137 Wrocław, Poland.ORCID 0000-0001-6641-0182
Hanna Makuch-ŁasicaInstitute of Hematology and Transfusion Medicine, 02-776 Warsaw, Poland.
Bożena JaźwiecDepartment of Hematology, Blood Neoplasms and Bone Marrow Transplantation, Medical University of Wrocław, 50-137 Wrocław, Poland.
Monika PaluszewskaDepartment of Hematology, Transplantation and Internal Medicine, Medical University of Warsaw, 02-091 Warsaw, Poland.
Beata Piątkowska-JakubasDepartment of Hematology, Jagiellonian University Medical College, 31-008 Cracow, Poland.
Magdalena ZawadaDepartment of Hematology, Jagiellonian University Medical College, 31-008 Cracow, Poland.ORCID 0000-0001-9105-1767
Michał GniotDepartment of Hematology and Bone Marrow Transplantation, Poznań University of Medical Sciences, 61-701 Poznań, Poland.
Joanna TrubickaChildren's Memorial Health Institute, 04-736 Warsaw, Poland.ORCID 0000-0002-9848-3674
Magdalena SzymańskaDepartment of Hematology, Transplantation and Internal Medicine, Medical University of Warsaw, 02-091 Warsaw, Poland.ORCID 0009-0001-3646-4902
Katarzyna BorgInstitute of Hematology and Transfusion Medicine, 02-776 Warsaw, Poland.
Marta WięsikDepartment of Hematology, Transplantation and Internal Medicine, Medical University of Warsaw, 02-091 Warsaw, Poland.
Sylwia CzekalskaDepartment of Hematology, Jagiellonian University Medical College, 31-008 Cracow, Poland.
Izabela FlorekDepartment of Hematology, Jagiellonian University Medical College, 31-008 Cracow, Poland.
Maria KrólDepartment of Hematology, Transplantation and Internal Medicine, Medical University of Warsaw, 02-091 Warsaw, Poland.
Małgorzata Paszkowska-KowalewskaDepartment of Hematology, Transplantation and Internal Medicine, Medical University of Warsaw, 02-091 Warsaw, Poland.
Lidia GilDepartment of Hematology and Bone Marrow Transplantation, Poznań University of Medical Sciences, 61-701 Poznań, Poland.
Katarzyna Kapelko-SłowikDepartment of Hematology, Blood Neoplasms and Bone Marrow Transplantation, Medical University of Wrocław, 50-137 Wrocław, Poland.
Elżbieta PatkowskaInstitute of Hematology and Transfusion Medicine, 02-776 Warsaw, Poland.ORCID 0000-0001-8691-4310
Agnieszka TomaszewskaDepartment of Hematology, Transplantation and Internal Medicine, Medical University of Warsaw, 02-091 Warsaw, Poland.
Krzysztof MądryDepartment of Hematology, Transplantation and Internal Medicine, Medical University of Warsaw, 02-091 Warsaw, Poland.
Rafał MachowiczDepartment of Hematology, Transplantation and Internal Medicine, Medical University of Warsaw, 02-091 Warsaw, Poland.
Tomasz CzerwMaria Skłodowska-Curie National Research Institute of Oncology, Gliwice Branch, 44-102 Gliwice, Poland.ORCID 0000-0003-3108-4035
Agnieszka PiekarskaDepartment of Hematology and Transplantology, Medical University of Gdańsk, 80-214 Gdańsk, Poland.ORCID 0000-0002-1593-8005
Magdalena DutkaDepartment of Hematology and Transplantology, Medical University of Gdańsk, 80-214 Gdańsk, Poland.ORCID 0000-0001-8112-3974
Anna KopińskaDepartment of Hematology and Bone Marrow Transplantation, Medical University of Silesia, 40-032 Katowice, Poland.
Grzegorz HelbigDepartment of Hematology and Bone Marrow Transplantation, Medical University of Silesia, 40-032 Katowice, Poland.
Tomasz GromekDepartment of Hematooncology and Bone Marrow Transplantation, Medical University of Lublin, 20-081 Lublin, Poland.
Krzysztof LewandowskiDepartment of Hematology and Bone Marrow Transplantation, Poznań University of Medical Sciences, 61-701 Poznań, Poland.ORCID 0000-0003-0992-2020
Marta ZacharczukDepartment of Hematology, Blood Neoplasms and Bone Marrow Transplantation, Medical University of Wrocław, 50-137 Wrocław, Poland.
Anna PastwińskaDepartment of Tumor Biology and Genetics, Medical University of Warsaw, 02-106 Warsaw, Poland.ORCID 0000-0002-0519-1104
Tomasz WróbelDepartment of Hematology, Blood Neoplasms and Bone Marrow Transplantation, Medical University of Wrocław, 50-137 Wrocław, Poland.
Olga HausDepartment of Clinical Genetics, Faculty of Medicine, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University, 87-100 Toruń, Poland.
Grzegorz BasakDepartment of Hematology, Transplantation and Internal Medicine, Medical University of Warsaw, 02-091 Warsaw, Poland.ORCID 0000-0003-3858-8180
Jerzy HołowieckiMaria Skłodowska-Curie National Research Institute of Oncology, Gliwice Branch, 44-102 Gliwice, Poland.
Przemysław JuszczyńskiInstitute of Hematology and Transfusion Medicine, 02-776 Warsaw, Poland.ORCID 0000-0001-7215-0444
Ewa Lech-MarańdaInstitute of Hematology and Transfusion Medicine, 02-776 Warsaw, Poland.
Sebastian GiebelMaria Skłodowska-Curie National Research Institute of Oncology, Gliwice Branch, 44-102 Gliwice, Poland.
Wiesław Wiktor JędrzejczakDepartment of Hematology, Transplantation and Internal Medicine, Medical University of Warsaw, 02-091 Warsaw, Poland.
Medical University of Warsaw · PLInstytut Hematologii i Transfuzjologi · PLUniversity of Wrocław · PLJagiellonian University · PLPoznan University of Medical Sciences · PLThe Maria Sklodowska-Curie National Research Institute of Oncology · PLGdańsk Medical University · PLMedical University of Silesia · PLChildren's Memorial Health Institute · PLMedical University of Lublin · PLNicolaus Copernicus University · PL

Funding

National Science Center 2015/19/N/NZ5/03495
6 · The paper itself

Abstract

Adult acute lymphoblastic leukemia (ALL) is associated with poor outcomes. ALL is initiated by primary aberrations, but secondary genetic lesions are necessary for overt ALL. In this study, we reassessed the value of primary and secondary aberrations in intensively treated ALL patients in relation to mutator enzyme expression. RT-PCR, genomic PCR, and sequencing were applied to evaluate primary aberrations, while qPCR was used to measure the expression of RAG and AID mutator enzymes in 166 adult ALL patients. Secondary copy number alterations (CNA) were studied in 94 cases by MLPA assay. Primary aberrations alone stratified 30% of the patients (27% high-risk, 3% low-risk cases). The remaining 70% intermediate-risk patients included

Indexed as

acute lymphoblastic leukemiacopy number alterationsprimary aberrationssecondary aberrations

Identifiers

PMID38001691
PMCPMC10670434
OpenAlexW4388694868

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.